Skip to main content
SpringerLink
Log in

Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands

  • Letter
  • Published:
Advances in Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Levrat-Guillen F, De Cock P. Cost-effectiveness of hybrid closed-loop systems versus multiple daily injections plus intermittently-scanned continuous glucose monitoring in type 1 diabetes in the Netherlands: Comment on Serné et al. Adv Ther. 2022.

  2. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022;10(10):720–31.

    Article  CAS  PubMed  Google Scholar 

  3. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(4):583–9.

    Article  CAS  PubMed  Google Scholar 

  4. Charleer S, Block CD, Huffel LV, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43:389–97.

    Article  PubMed  Google Scholar 

  5. Wilmot EG, Leelarathna L, Evans ML, Neupane S, Rayman G, Lumley S. FLASH-UK randomised controlled trial. In: Diabetes UK professional conference 2022. 2022.

  6. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7:e000809.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cordero TL, Garg SK, Brazg R, et al. The effect of prior continuous glucose monitoring use on glycemic outcomes in the pivotal trial of the MiniMed™ 670G hybrid closed-loop system. Diabetes Technol Ther. 2017;19:749–52.

    Article  PubMed  Google Scholar 

  8. McAuley SA, Lee MH, Paldus B, et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. Diabetes Care. 2020;43:3024–33.

    Article  CAS  PubMed  Google Scholar 

  9. Lepore G, Scaranna C, Corsi A, Dodesini AR, Trevisan R. Switching from suspend-before-low insulin pump technology to a hybrid closed-loop system improves glucose control and reduces glucose variability: a retrospective observational case-control study. Diabetes Technol Ther. 2020;22(4):321–5.

    Article  PubMed  Google Scholar 

  10. Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Carlson AL, Sherr JL, Shulman DI, et al. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2021. https://doi.org/10.1089/dia.2021.0319.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Petrovski G, Al Khalaf F, Campbell J, et al. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol. 2021;58(2):207–13.

    Article  CAS  PubMed  Google Scholar 

  13. Levrat-Guillen F, Ghazi T. Cost-effectiveness of intermittently scanned continuous glucose monitoring versus advanced hybrid closed-loop systems in type 1 diabetes: comment on Jendle et al. Diabetes Ther. 2022;13(5):1121–3.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Jendle J, Buompensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O. A response to: letter to the editor with regard to the cost-effectiveness of an advanced hybrid closed-loop system in people with type 1 diabetes: a health economic analysis in Sweden. Diabetes Ther. 2022;13(5):1125–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nørgaard K, Scaramuzza A, Bratina N, et al. Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther. 2013;15:273–80.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Al Hayek AA, Robert AA, Al Dawish MA. Evaluation of FreeStyle libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10(10):1179551417746957.

    PubMed  PubMed Central  Google Scholar 

  17. Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397(10291):2275–83.

    Article  CAS  PubMed  Google Scholar 

  18. Anderbro T, Amsberg S, Adamson U, et al. Fear of hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2010;27(10):1151–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding

Funding for this response letter was provided by Medtronic International Trading Sàrl.

Medical Writing and/or Editorial Assistance

Medical writing and editorial support for the response letter was provided by Richard Pollock at Covalence Research Ltd.

Author Contributions

All authors contributed to the response letter. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Erik H Serné is an employee of Amsterdam UMC. Stéphane Roze is an employee of Vyoo Agency. Maria Ida Buompensiere and Simona De Portu are employees of Medtronic International Trading Sàrl. William Valentine is a director and employee of Ossian Health Economics and Communications GmbH, which received consulting fees to support preparation of the cost-effectiveness manuscript. Harold W de Valk is an employee of University Medical Center, Utrecht.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Author information

Authors and Affiliations

  1. Amsterdam UMC, Amsterdam, The Netherlands

    Erik H. Serné

  2. Vyoo Agency, Lyon, France

    Stéphane Roze

  3. Medtronic International Trading Sàrl, Tolochenaz, Switzerland

    Maria I. Buompensiere & Simona de Portu

  4. Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland

    William J. Valentine

  5. University Medical Center, Utrecht, The Netherlands

    Harold W. de Valk

Authors
  1. Erik H. Serné
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphane Roze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria I. Buompensiere
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William J. Valentine
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simona de Portu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Harold W. de Valk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Valentine.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Serné, E.H., Roze, S., Buompensiere, M.I. et al. Response to: Letter to the Editor with Regard to the Cost-Effectiveness of Hybrid Closed-Loop Systems Versus Multiple Daily Injections Plus Intermittently Scanned Continuous Glucose Monitoring in Type 1 Diabetes in the Netherlands. Adv Ther 40, 2545–2548 (2023). https://doi.org/10.1007/s12325-023-02431-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-023-02431-2

Keywords

Search

Navigation